Drugs / OctaAlpha1
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03385395 | Jul 2018 → Dec 2019 | alpha 1-antitrypsin deficiency | Octapharma | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OctaAlpha1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03385395 ↗ |
| Route | Intravenous | “Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia®” NCT03385395 ↗ |